Cargando…

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.

Novel imidazoacridinone derivatives, C1310 and C1311, have been evaluated for their potential to inhibit tumour cell growth in vitro and in vivo. A cell line panel, including seven human and murine colon carcinoma cell lines and three in vivo models, was used. The compounds were found to be potent i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, A. M., Double, J. A., Konopa, J., Bibby, M. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074789/ https://www.ncbi.nlm.nih.gov/pubmed/8912531

Ejemplares similares

Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311
por: Burger, A M, et al.
Publicado: (1999)

The Effect of Conjugation with Octaarginine, a Cell-Penetrating Peptide on Antifungal Activity of Imidazoacridinone Derivative
por: Rząd, Kamila, et al.
Publicado: (2021)

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
por: Laws, A. L., et al.
Publicado: (1995)

Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers
por: Adar, Y, et al.
Publicado: (2012)

Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells
por: Niemira, Magdalena, et al.
Publicado: (2020)

Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy.
por: Burger, A. M., et al.
Publicado: (1997)

Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation.
por: Lamb, J., et al.
Publicado: (1996)

Photodynamic Inactivation of Candida albicans with Imidazoacridinones: Influence of Irradiance, Photosensitizer Uptake and Reactive Oxygen Species Generation
por: Taraszkiewicz, Aleksandra, et al.
Publicado: (2015)

The imidazoacridinone C-1311 induces p53-dependent senescence or p53-independent apoptosis and sensitizes cancer cells to radiation
por: Skwarska, Anna, et al.
Publicado: (2017)

Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis
por: Świtalska, Marta, et al.
Publicado: (2022)

Characterisation and chemosensitivity of a well-differentiated murine transplantable adenocarcinoma of the colon.
por: Double, J. A., et al.
Publicado: (1983)

Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
por: Bibby, M. C., et al.
Publicado: (1981)

Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).
por: Bibby, M. C., et al.
Publicado: (1988)

Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.
por: Double, J. A., et al.
Publicado: (1986)

The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours.
por: Bibby, M. C., et al.
Publicado: (1991)

In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.
por: Phillips, R. M., et al.
Publicado: (1992)

EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
por: Collard, J., et al.
Publicado: (1995)

The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.
por: Bibby, M. C., et al.
Publicado: (1988)

Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.
por: Bibby, M. C., et al.
Publicado: (1991)

Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus
por: Good, Steven S., et al.
Publicado: (2020)

Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).
por: Bibby, M. C., et al.
Publicado: (1987)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

In Silico Discovery of Novel Potent Antioxidants on the Basis of Pulvinic Acid and Coumarine Derivatives and Their Experimental Evaluation
por: Martinčič, Rok, et al.
Publicado: (2015)

Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
por: Bibby, M. C., et al.
Publicado: (1992)

Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer
por: Zaytseva, Yekaterina Y., et al.
Publicado: (2018)

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
por: Lieu, Christopher H., et al.
Publicado: (2015)

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2014)

Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities
por: Basilico, Nicoletta, et al.
Publicado: (2023)

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2019)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Synthetic hookworm-derived peptides are potent modulators of primary human immune cell function that protect against experimental colitis in vivo
por: Smallwood, Taylor B., et al.
Publicado: (2021)

Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells
por: Skladanowski, A, et al.
Publicado: (2000)

Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
por: Li, Gaowei, et al.
Publicado: (2021)

Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma
por: Zhu, Bing, et al.
Publicado: (2023)

Novel Gallate Triphenylphosphonium Derivatives with Potent Antichagasic Activity
por: Cortes, Leonel A., et al.
Publicado: (2015)

Heliotropium ramosissimum metabolic profiling, in silico and in vitro evaluation with potent selective cytotoxicity against colorectal carcinoma
por: Fayed, Marwa A. A., et al.
Publicado: (2022)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
por: Pitts, Todd M., et al.
Publicado: (2016)

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
por: Klauck, Peter J., et al.
Publicado: (2018)

RK‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model
por: Mizutani, Anna, et al.
Publicado: (2018)

Mouse models of colorectal cancer as preclinical models
por: McIntyre, Rebecca E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mcft53c12kchb9c3u0ndkogku5